Effectiveness of D-Rd program in the first line therapy of a 75-year-old female patient with multiple myeloma with high-risk cytogenetics. Clinical observation

Cover Page

Cite item

Full Text

Abstract

Multiple myeloma is a B-cell lymphoproliferative disorder. Morphological substrate of the disorder are plasma cells producing monoclonal immunoglobulin, and the disorder is characterized by heterogeneity of clinical manifestations. Due to the understanding of molecular and biological basics of multiple myeloma pathogenesis, significant success was achieved in treatment of the standard and high-risk cytogenetics groups including full remission. However, not all patients show long-term progression-free survival. Necessity of more accurate evaluation of the extent of antitumor response, prognosis of progression-free survival and recurrence development led to minimal residual disease (MRD) testing. The analysis is based on detection of phenotypically aberrant clonal plasma cells in bone marrow aspirate after drug treatment. Currently, MRD-negative status is a significant prognostic factor. In some studies, high effectiveness of daratumumab in achievement of MRD-negative status in elderly patients with newly diagnosed multiple myeloma was demonstrated.

About the authors

Yu. E. Ryabukhina

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

Author for correspondence.
Email: gemonk.yur@mail.ru
ORCID iD: 0000-0001-8443-8816

Yulia E. Ryabukhina

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Russian Federation

F. M. Abbasbeyli

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0000-0002-2359-0547

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Russian Federation

P. A. Zeynalova

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies;
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

ORCID iD: 0000-0003-1564-424X

Department of Oncology I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081,

Bld. 2, 8 Trubetskaya St., Moscow 119991

Russian Federation

O. L. Timofeeva

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0000-0002-6229-7300

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Russian Federation

N. A. Kupryshina

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0001-8509-0954

24 Kashirskoe shosse, Moscow 115478

Russian Federation

A. G. Zhukov

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Russian Federation

References

  1. Mendeleeva L.P., Votiakova O.M., Rekhtina I.G. et al. Multiple myeloma. Clinical recommendations. Sovremennaya onkologiya = Journal of Modern Oncology 2020;22(4):6–28. (In Russ.). doi: 10.26442/18151434.2020.4.200457
  2. Kuehl W.M., Bergsagel P.L. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 2012;122(10):3456–63. doi: 10.1172/JCI61188
  3. Moreau P., San Miguel J., Sonneveld P. et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(Suppl 4):iv52–iv61. doi: 10.1093/annonc/mdx096
  4. Palumbo A., Avet-Loiseau H., Oliva S. et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol Am Soc Clin Oncol 2015;33(26):2863–9. doi: 10.1200/JCO.2015.61.2267
  5. Weisel K., Doyen C., Dimopoulos M. et al. A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation. Leuk Lymphoma 2017;58(1):153–61. doi: 10.1080/10428194.2016.1177772
  6. Mateos M.V., Richardson P.G., Schlag R. et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010;28(13):2259–66. doi: 10.1200/JCO.2009.26.0638
  7. Benboubker L., Dimopoulos M.A., Dispenzieri A. et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 2014;371(10):906–17. doi: 10.1056/NEJMoa1402551
  8. Tolstykh E.E., Tupitsyn N.N. Key markers for diagnosis of minimal residual disease in multiple myeloma. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotheray 2022;21(1):42–9. (In Russ.). doi: 10.17650/1726-9784-2022-21-1-42-49.
  9. Grivtsova L.Yu., Lunin V.V., Semenova A.A. et al. Minimal residual disease in plasma cell (multiple) myeloma: flow cytometric approaches. Onkogematologiya = Oncohematology 2020;15(1):40–50. (In Russ.) doi: 10.17650/1818-8346-2020-15-1-40-50
  10. Munshi N.C., Avet-Loiseau H., Rawstron A.C. et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol 2017;3(1):28–35. doi: 10.1001/jamaoncol.2016.3160
  11. Perrot A., Lauwers-Cances V., Corre J. et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood 2018;132(23):2456–64. doi: 10.1182/blood-2018-06-858613
  12. Avet-Loiseau H., Ludwig H., Landgren O. et al. Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a meta-analysis. Clin Lymphoma Myeloma Leuk 2020;20(1):e30–e7. doi: 10.1016/j.clml.2019.09.622
  13. Dimopoulos M.A., Oriol A., Nahi H. et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;375(14): 1319–31. doi: 10.1056/NEJMoa1607751
  14. Lokhorst H.M., Plesner T., Laubach J.P. et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 2015;373(13):1207–19. doi: 10.1056/NEJMoa1506348
  15. Mateos M.V., Dimopoulos M.A., Cavo M. et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med 2018;378(6):518–28. doi: 10.1056/NEJMoa1714678
  16. de Weers M., Tai Y.T., van der Veer M.S. et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011;186(3):1840–8. doi: 10.4049/jimmunol.1003032
  17. Facon T., Kumar S., Plesner T. et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 2019;380(22):2104–15. doi: 10.1056/NEJMoa1817249
  18. Facon T., Cook G., Usmani S.Z. et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia 2022;36(4):1066–77.
  19. Kumar S., Paiva B., Anderson K.C. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17(8):e328–e46. doi: 10.1016/S1470-2045(16)30206-6
  20. Paiva B., Vidriales M.B., Cerveró J. et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008;112(10):4017–23. doi: 10.1182/blood-2008-05-159624
  21. Martinez-Lopez J., Lahuerta J.J., Pepin F. et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 2014; 123(20):3073–9. doi: 10.1182/blood-2014-01-550020
  22. Rawstron A.C., Gregory W.M., de Tute R.M. et al. Minimal residual disease in myeloma by flow cytometry: Independent prediction of survival benefit per log reduction. Blood 2015;125(12):1932–5. doi: 10.1182/blood-2014-07-590166
  23. Paiva B., Gutiérrez N.C., Rosiñol L. et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2012;119(3):687–91. doi: 10.1182/blood-2011-07-370460
  24. Lahuerta J.J., Paiva B., Vidriales M.B. et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials. J Clin Oncol 2017;35(25):2900–10. doi: 10.1200/JCO.2016.69.2517
  25. Rawstron A.C., Child J.A., de Tute R.M. et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: Impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 2013;31(20):2540–7. doi: 10.1200/JCO.2012.46.2119
  26. Korde N., Roschewski M., Zingone A. et al. Treatment with carfilzomiblenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol 2015;1(6):746–54. doi: 10.1001/jamaoncol.2015.2010
  27. Paiva B., van Dongen J.J., Orfao A. New criteria for response assessment: Role of minimal residual disease in multiple myeloma. Blood 2015;125(20):3059–68. doi: 10.1182/blood-2014-11-568907

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 ABV-Press

License URL: https://mdonco.abvpress.ru/jour/about/editorialPolicies
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-81466 от  03.08.2021.